Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push - Reuters
Eli Lilly is acquiring three vaccine developers for up to $3.8B, pushing into infectious disease as a strategic diversification from its GLP-1/diabetes dominance. The deal is modest relative to Lilly's ~$1T market cap but signals a pipeline pivot that could re-rate sentiment if vaccine assets de-risk over the next 12-18 months.
What happened
Eli Lilly is acquiring three vaccine developers for up to $3.8B, pushing into infectious disease as a strategic diversification from its GLP-1/diabetes dominance.
The read · May 26
Buy LLY dips into the $1040-1050 range — $3.8B deal is small enough to be digestible, adds pipeline optionality, and BofA just revamped its price target; consensus remains heavily Buy-skewed with 30 Buy/SB vs 1 Sell.
Wrong if
Two insider sells in the last 30 days with zero buys is a mild red flag at these levels; if BofA's revised target comes in below the prior one, sentiment could flip negative quickly. Additionally, if any of the three vaccine targets face clinical setbacks early in the integration timeline, the deal could be re-framed as capital misallocation given Lilly's already-stretched GLP-1 R&D spend.
CoverageSource: Google News · Published here TUE, MAY 26 · 12:26 PM ET · the only report in this recordHow this is decided →
The chart · LLYTradingView · third-party feed, not the Wire’s licensed closes
🔒 Click to interact · scroll moves the page
The story1 min read
The read, in fullWhy it matters
The $3.8B acquisition represents less than 0.4% of Lilly's market cap, so dilution risk is negligible and the strategic optionality in infectious disease is essentially free from a balance-sheet perspective. Consensus sits at 30 Buy/Strong Buy vs 1 Sell — already crowded, but BofA's same-day price-target revision suggests sell-side is still constructive post-deal. The modest stock reaction (flat on the day) implies the market hasn't fully priced in the pipeline narrative, creating a marginal entry opportunity on any near-term weakness.
The arc● Open · no developments yet
· Published
The read above, as written. kept as written
Next · what would move this
4-8 weeks. Follow to be told when one lands.
Receipts
Google News — the original12:26 PM
Research, not advice.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →